Navigation Links
GUMC researchers find gene function 'lost' in melanoma and glioblastoma
Date:12/14/2008

Washington, D.C. Researchers at Georgetown University Medical Center have found a gene they say is inactivated in two aggressive cancers malignant melanoma, a form of skin cancer, and glioblastoma multiforme, a lethal brain tumor. They add that because this gene, known as PTPRD, has recently been found to be inactivated in several other cancers as well, their discovery suggests that PTPRD may play a tumor suppressor role in a wide variety of different cancers.

The findings are published in the December 15 issue of Cancer Research.

"Over the past decade several dozen tumor suppressor genes have been identified, but only a minority of them is important in causing many different tumor types. PTPRD seems to be one of these broad spectrum tumor suppressor genes," says the study's lead investigator, Todd Waldman, MD, PhD, an associate professor of oncology at Georgetown's Lombardi Comprehensive Cancer Center.

If the hypothesis is true and Waldman and his team are now investigating loss of PTPRD in a number of additional cancers then it may be possible to design a therapy that has wide applicability in oncology, he says.

"Most targeted cancer drugs today work by inhibiting gene products that are overactive in cancer cells. In this case, it is loss of the PTPRD gene that leads to cancer," Waldman says. "Therefore, we are trying to discover the molecules that PTPRD's protein controls, and then we plan to target these downstream molecules with a novel agent."

Waldman found that when the researchers restored production of the gene's protein in cancer cells that harbored PTPRD deletions or mutations, these tumors stopped growing and initiated a program of cell suicide.

The researchers also discovered PTPRD mutations in both the blood and in tumors of a patient with multiple different kinds of cancers. "This suggests that the gene could be responsible for an inherited predisposition to cancer," Waldman says


'/>"/>
Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015 Passwords have ... seen in the recent U.S. Office of Personnel ... to the infosec conundrum, but developers and end-users ... To address this dilemma, Biometrics-as-a-Service provider HYPR Corp. ... Tokenization SDK for third party integration. ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), a ... it will report financial results for the fourth quarter ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... The changes to the publication requirements of new ... XVIII International Botanical Congress in Melbourne in July 2011 ... To address practical questions arising from the Congress decisions, the ... a series of seven exemplar papers, one each day for ...
... the Greek word for "glue," hold the brain,s neurons together ... but scientists have long puzzled over their prominence in the ... Tel Aviv University researchers say that glia cells are central ... and stores information. According to Ph.D. student Maurizio ...
... the Gobi desert are usually long and very cold ... of livestock died in Mongolia and the re-introduced wild ... Walzer from the University of Veterinary Medicine, Vienna have ... GPS telemetry to provide insights into the effect of ...
Cached Biology News:Brave new world 2Brave new world 3Brain's connective cells are much more than glue 2Brain's connective cells are much more than glue 3Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 2Don't put all your eggs in 1 basket -- or all your horses on 1 pasture 3
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is ... of partially hydrolyzed gluten in foods, has been accepted by AOAC International as ... Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a ...
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
Breaking Biology Technology:RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9
... 13 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... on commercializing proprietary product candidates for the ... that Evan M. Levine,ADVENTRX,s chief executive officer, ... Fifth Annual Growth Conference on Wednesday,September 19th, ...
... ... to inhibit ... 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 Isis,Pharmaceuticals, Inc. (Nasdaq: ISIS ...
... VANCOUVER, Sept. 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... today that it received a,favourable decision from ... an attempt by Johnson & Johnson,s subsidiary, ... Zealand Patent 523799, which,pertains to compositions comprising ...
Cached Biology Technology:ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: